Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM61NFD)

• Drug Name: PD-157667 Drug Info
• Synonyms: CHEMBL78017; PD-157667; SCHEMBL7307021; pd157667; BDBM50071611
• Cross-matching ID:
  PubChem CID: 9956291
  TTD Drug ID: DM61NFD

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[2]
Ziconotide	DMSLJP4	Pain	MG30-MG3Z	Approved	[3]
Hesperidin	DMI5DW1	Vascular purpura	3B60	Approved	[4]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[5]
Ralfinamide	DMUNMY0	Neuropathic pain	8E43.0	Phase 3	[6]
CNV-2197944	DMLT7JV	Pain	MG30-MG3Z	Phase 2	[7]
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[8]
CNSB-004	DMHAI0M	Pain	MG30-MG3Z	Preclinical	[9]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[10]
PD-0204318	DMGKVPH	Pain	MG30-MG3Z	Terminated	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)	TT4FDG6	CAC1B_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [2] Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
• [3] Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
• [4] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [5] N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
• [6] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [7] Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
• [8] N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
• [9] CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [11] US patent application no. 2012,0172,429, Permanently charged sodium and calcium channel blockers as anti- inflammatory agents.